Search for content, post, videos

A new Swedish immunotherapeutic cancer vaccine delivery-platform

Sara Mangsbo Photo Mikael Wallerstedt
SciLifeLab Group leader, Sara Mangsbo, Uppsala University, and her immunotherapeutic cancer vaccine delivery-platform, is now ready to leave the SciLifeLab Drug Discovery and Development platform (DDD). The immunotherapeutic cancer vaccine delivery platform is based on a new technique, called Ada
Already a subscriber Login

You have read all your free articles, to continue reading subscribe to read the rest of this content.